TGF-β Signaling and Resistance to Cancer Therapy

Zhang, Maoduo; Zhang, Yingyi; Chen, Yongze; Jia, Wang; Wang, Qiang; Lu, Hezhe

doi:10.3389/fcell.2021.786728

Cited by 108 publications

(65 citation statements)

References 167 publications

(227 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This suggests that TGF-β signaling changes during tumor progression from tumor suppression to tumor promotion. TGF-β has been found to induce tumor resistance to chemotherapy through multiple pathways [ 114 ]. For example, the miRNA-mediated activation of the TGF-β signaling pathway can increase DNA repair capacity, leading to tumor drug resistance [ 115 ].…”

Section: The Signaling Pathways In Tumor Drug Resistancementioning

confidence: 99%

Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways

et al. 2022

View full text Add to dashboard Cite

Drug resistance is still an obstacle in cancer therapy, leading to the failure of tumor treatment. The emergence of tumor drug resistance has always been a main concern of oncologists. Therefore, overcoming tumor drug resistance and looking for new strategies for tumor treatment is a major focus in the field of tumor research. Natural products serve as effective substances against drug resistance because of their diverse chemical structures and pharmacological effects. We reviewed the signaling pathways involved in the development of tumor drug resistance, including Epidermal growth factor receptor (EGFR), Renin-angiotensin system (Ras), Phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), Wnt, Notch, Transforming growth factor-beta (TGF-β), and their specific signaling pathway inhibitors derived from natural products. This can provide new ideas for the prevention of drug resistance in cancer therapy.

show abstract

Section: The Signaling Pathways In Tumor Drug Resistancementioning

confidence: 99%

Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Despite the encouraging potential displayed by TGF-β-targeted drugs in a part of pre-clinical animal studies, the results from subsequent clinical trials of those drugs seem to be disappointing. The application of TGF-β inhibition strategies in patients with fibrosis is challenging due to the systemic effects of TGF-β and the complexity of cancer and fibrosis formation [ 227 ]. Firstly, although TGF-β cascades are commonly activated to contribute to pathological processes, the physiological function of TGF-β cannot be ignored.…”

Section: Introductionmentioning

confidence: 99%

Targeting TGF-β signal transduction for fibrosis and cancer therapy

et al. 2022

View full text Add to dashboard Cite

Transforming growth factor β (TGF-β) has long been identified with its intensive involvement in early embryonic development and organogenesis, immune supervision, tissue repair, and adult homeostasis. The role of TGF-β in fibrosis and cancer is complex and sometimes even contradictory, exhibiting either inhibitory or promoting effects depending on the stage of the disease. Under pathological conditions, overexpressed TGF-β causes epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) deposition, cancer-associated fibroblast (CAF) formation, which leads to fibrotic disease, and cancer. Given the critical role of TGF-β and its downstream molecules in the progression of fibrosis and cancers, therapeutics targeting TGF-β signaling appears to be a promising strategy. However, due to potential systemic cytotoxicity, the development of TGF-β therapeutics has lagged. In this review, we summarized the biological process of TGF-β, with its dual role in fibrosis and tumorigenesis, and the clinical application of TGF-β-targeting therapies.

show abstract

“…Data on TGFB expression was also equivocal. TGFβ signaling is often dysregulated in human cancer, with tumor suppressive function in premalignant and early-stage lesions and oncogenic effects in more advanced lesions ( Zhang et al., 2021 ). One study found TGFB mRNA levels to be decreased in tumors from OTRs ( P = 0.036) ( Kosmidis et al., 2010 ), whereas another showed TGFβ staining to be more intense among the RTR population ( P = 0.049) ( Gutiérrez-Dalmau et al., 2010 ).…”

Section: Resultsmentioning

confidence: 99%